Market News

The expansion plans include an additional manufacturing line, a new cleanroom and a new process development lab

As CDMOs seek to diversify their business models, is a full-service offering the holy grail or is there a danger of biopharmaceutical outsourcing firms becoming the jack of all trades and the master of none?

The CDMO, through its recent acquisition of IsiSys, will help to advance BICX104 toward first-in-human clinical trials

The new area will produce proteins using innovative and highly sustainable processes such as microbial fermentation

Investment will further expand CDMO's global network of SUT facilities to boost reliable supply of critical materials used to produce new biologics and vaccines

Opportunities for CDMO expansion are extending to Latin America and Africa, say experts

The CDMO will manufacture drug substance and drug product for Phase II clinical trials in AML patients

Japan's biggest drugmaker prepares to make the vaccine domestically and anticipates early 2022 distribution

The CDMO significantly increases its footprint, capacity and capabilities to meet current and future demand

The new Switzerland-based CDMO differentiates itself by its sustainable vision of making a positive impact for people and planet

The facility will be able to manufacture and stockpile a five-year supply of amoxicillin for the US

The agreement is expected to accelerate Cipla’s global lung leadership agenda

£35 million public-private collaboration to develop next-generation pharmaceutical manufacturing processes to drive forward innovation in the medicines supply chain

The CDMO inaugurates its new analytical laboratory under Recipharm Analytical Solutions

The new facility will augment the company's capacity to broaden its portfolio of perinatal-derived products

The new production line at Guangzhou site will supply global and domestic companies with clinical and commercial batches

The $35 million investment will more than double the site’s batch-size scaling and product output.

New site in Cardiff boosts the company's production capacity for equipment crucial in the supply chain for mRNA vaccines production

Firms say the partnership will "multiply the power of both companies, the pharmaceutical industry and the medical cannabis industry"

The solid oral dose specialist signs letter of intent for acquisition of a CDMO providing a full range of services

The new facility will provide access to domestically manufactured vaccines against respiratory viruses

The CPHI North America exhibition is taking place in-person this week in Philadelphia from 10-12 August. Here we take a look at key learnings from the past two weeks of expert-led content, available to all attendees as part of the hybrid event experien...

KYOWA Pharmaceutical Industry will be the CDMO's first Japanese client for its Zhunan manufacturing site

The expansion is Heraeus’ response to increasing global demand for these products in cancer treatment

The cosmetics packaging sector will need to respond to increasing consumer awareness of climate change by transitioning from fossil-based materials to long-term carbon neutral and carbon negative alternatives, according to industry experts speaking at ...

Tech transfer is a crucial phase that converts clinical promise into commercial gain but pressure on sponsors to reduce time to market in the age of COVID-19 means CDMOs have to be on top of their game to deliver. What are the latest innovations to sol...

The collaboration will see Catalent install a commercial-scale KinetiSol technology manufacturing line at its Somerset, New Jersey, facility

The purchase of BMS's Couvet, Switzerland facility adds commercial-scale production capacity for capsule and tablet dosage forms

The new approval of Semeglee allows pharmacy-level substitution for Lantus across the US

CDMOs need to diversify and expand their capabilities to take full advantage of strong growth in prominent end markets such as small molecule, monoclonal antibodies and cell and gene therapy, according to an industry expert on a panel at the CPHI North...

Acquiring Xell AG will enable Sartorius to offer specialised media for manufacturing viral vectors

Accelerated efforts align with the Paris Agreement and Race To Zero to combat climate change

The combined capabilities will offer flexibility and innovation from small-scale biosimilar development through to large-scale manufacturing

The investment will fund the construction of a Translational Science Center for its Healthcare business sector, as well as a new Learning Center

The acquisition will add manufacturing footprint in the US enabling the company to develop its pipeline of novel cancer product candidates

Samsung to provide end-to-end CDMO services to advance Kineta's novel anti-VISTA antibody for the treatment of solid tumours

Using Veratrak's platform, the CDMO will have full oversight of data, including an audit trail of data and document processes

Acquisition will add West Coast coverage to the CDMO's East Coast and European capabilities and enhance its biologics formulation development and fill-finish network

The company will use its orally disintegrating tablet technology Zydis for JOS Pharmaceuticals' licensed CBD product

The emerging biotech company unveils plans for a 1.2 million-sq. ft manufacturing facility in Yangzhou

China-based company could supply up to 380 million doses from July 2021 through to June 2022

The integrated CDMO rolls out services to the broader community of drug manufacturers and developers

A new media panel, gene kit and advanced resins help reduce manufacturing costs and increase the viability of gene therapies

The CDMO plans to roll out the ISO 45001 and ISO 14001 certification throughout multiple sites worldwide

Pharma firm tells FDA tech transfer to its own facility in Schaftenau, Austria is underway after regulator highlighted concerns about third party CDMO site in Italy

Move is part of US$500 million five-year investment programme by Moroccan government and consortium to establish vaccine and biotherapeutic manufacturing capacity in the country

Medalchemy facility now fully licensed to import, cultivate, extract, manufacture and export medical cannabis flower and extracts

The CDMO's fivefold capacity increase will provide early preclinical through to commercialisation support

Greenfield construction of the new facility is expected to start later this year

The company will invest €400 million per year to advance mRNA technology beyond the pandemic

The expansion of mid-scale capacity will enable the company to offer a smooth transition between early-phase and large-scale commercial production

This month we discuss what is driving M&A strategies in the pharma space, paying particular attention to how investors regard the potential for the growing but fragmented CDMO sector

The investment will provide capacity to support current and future demands for the rapidly evolving cell and gene therapy sector

Catch up on the latest trends and developments in patient centric drug development

IHL-216A may make sports safer and reduce the morbidity and mortality rates of people suffering serious head traumas

The agreement marks the second cell line development collaboration between the two companies

The expansion close to company's Martinsried headquarters includes a lyophilisation development centre for advanced therapy medicinal products

While the COVID-19 pandemic has created even greater demand for partnerships, CDMOs need to be aware that the needle has shifted, creating both opportunities and challenges and changing how the services industry does business

The company expects to complete its building and modernising plans in Turku by 2025

Drug categories impacted by travel restrictions expected to see higher sales levels in FY22

The French CDMO is also creating a new global resource for drug developers of ATMPs

XDC will provide a full range of development and manufacturing services in one centralised region

The expanded capacity and capabilities include the development of a dedicated Life Sciences Technology Center

New $30 million manufacturing facility in Burlington, Ontario, will allow company to manage R&D in-house and scale production without reliance on third-party manufacturers

Alliance to Zero aims to facilitate the transition of the pharma sector to reach net zero emissions target

Hameln plant which provides fill and finish for Pfizer-BioNTech COVID-19 shot should be fully operational within the week, CDMO says

The additional manufacturing suite at the CDMO's Songdo site is anticipated to be ready for cGMP operations within the first half of 2022

A new location in Raleigh-Durham, North Carolina, close to the CDMO's Center of Excellence, will double its current footprint

The specialist CDMO receives manufacturing licenses from Switzerland and Denmark to supply customers with live biotherapeutic medicines

The expansion will accelerate the progression and tech transfer of projects within the early clinical development phases

The purchase is part of $17 million capacity expansion, which is in addition to a wider $43 million investment into the company's Pennsylvania operations

The CDMO will support the production of hundreds of millions of doses from its facility in Incheon, South Korea.

Upstream raw materials suppliers seen as the main source of innovation in a growing industry driven by demand for more natural ingredients manufactured in clean, sustainable way

Extending its patient-centric BD Intevia™ Disposable Autoinjector platform, BD builds on past successes while meeting the requirements of new, highly viscous, high-volume biologics for chronic diseases

Novartis generics and biosimilars division will invest €150 million during the next 3-5 years at its Kundl, Austria and Palafolls, Spain sites while phasing out production of oral APIs at Les Franqueses site

The UK’s withdrawal from the European Union has meant the pharmaceutical industry has had to adapt to some monumental changes in terms of research, regulatory affairs, and trade. In this CPHI Webinar, three industry experts discussed what the fut...

CDMO's site becomes the first vaccine production facility in South Korea to obtain EU GMP certification, allowing it to ship to Europe

The plan includes the creation of more than 30 full-time jobs at the CDMO's Le Mans site

The CDMO's expertise and capabilities a "perfect fit" for overcoming the challenges of manufacturing this complex molecule

New facility at Gosselies site will host commercial scale pDNA manufacturing as Catalent extends its cell and gene therapy footprint

In the future pharma companies will need to work closer with excipient companies if we are to develop better formulations more quickly

The addition of two new manufacturing trains will support the demand for high-value biopharmaceutical products

Industrial assets purchaser is offering high-capacity production line equipment formerly owned by bankrupt CMO

The expansion will support a 50% increase in production of biotech's COVID-19 vaccine at its manufacturing site

The software consulting company claims its software solution has already saved one pharma company €10.5 million

Biotech ties up deal three days after World Health Organization issued an emergency use listing for the mRNA vaccine

Sweeping ban includes APIs, intermediates and prescription and OTC medicines and comes amid tight regulatory requirements and the "high risk nature" of pharma products, e-commerce giant says

The new business alliance will support new product launches for specialty pharmaceutical manufacturers looking to enter the Japanese market

French company is now providing manufacturing capacity to support three different COVID-19 vaccines

CHF 200 million investment will include dedicated line for antibody-drug conjugate payload molecules and is scheduled to start operations in Q3 2023

Company failed to investigate vaccine drug substance discrepancies thoroughly, says US regulator

The company will expand multiple facilities in Hyderabad and Bangalore to help reach its target of approximately 700 million doses per year of the COVID-19 vaccine

The expanded agreement will ensure Rocket Pharma's supply of lentiviral vectors across its pipeline

Extra supply will bring total number of doses scheduled to be shipped to EU this year to 600 million

The expansions will enable the company's local customers to test equipment directly at the manufacturing site

Informa Markets' first in-person trade show of the year welcomes attendees in Tokyo as face-to-face interaction recommences among pharma community

The antibody-based products will be expressed using Lonza's GS Xceed Gene Expression System

The global CMO plans to have a complete, licensed cGMP manufacturing facility online by the end of 2021

The company's custom single run single-use fermenters supplied on fast-track schedule to support flexible manufacturing of plasmid DNA

The smallpox vaccine specialist will manufacture and deliver bulk drug substance of MVA-BN Filo vaccine during the second half of this year

The extended collaboration comes after reaching the initial milestone of producing 100 million doses

By integrating its HPAPI capabilities with those at ADC Biotechnologies' Deeside facility, small molecule CDMO will be able to offer the development and manufacturing of toxin linkers

Ploermel and Edinburgh facilities employ around 390 permanent staff and will allow UK CDMO to expand its technology offering

The US facility in Rockville is expected to accelerate the company’s commercial-scale manufacturing timelines of gavo-cel

The CDMO will provide cell line development, process development, drug substance and drug product manufacturing for Pionyr’s monoclonal antibody candidate

The former Rohner's manufacturing assets will enable omega-3 heavyweight to manufacture difficult, multi-step pharmaceutical intermediates and APIs

Pharma company will provide fill and finish manufacturing capacity at its Barnard Castle facility as early as the beginning of May 2021

Some seaborne deliveries are being rerouted or switched to air transportation as efforts to re-float stricken Ever Given container vessel move into fourth day

Company will use extension of Schedule I licence to start development of psychedelics-based pipeline to treat mental health disorders

The company will triple its capacity and workforce at its North Carolina site to increase its global capabilities and reach

The CDMO's Zydis technology will help the Canadian biotech to develop fast-acting, shorter-duration formulations of its potential therapy for treatment-resistant psychiatric disorders

Despite COVID-related challenges and supply chain issues, the CDMO's $240 million new facility is on target to open next year

The move ensures the service provider has the capacity to meet the needs of an evolving clinical market

US-headquartered company Kindeva seals deal for an R&D facility at Loughborough’s life sciences hub

Regulators stress temporary halt is precautionary measure and that there is currently no evidence linking the shot to adverse events

Tremendous growth opportunities exist for auto-injectors as their value is increasingly being recognised across several therapy areas, experts have told a recent CPHI webinar, sponsored by Stevanato Group.

The purchase will allow the company to add nine new customers to its growing CDMO business and 27 manufacturing suites

The enhancements will include installing the lever-operated multi-dose inhaler device used in Hikma’s generic Advair product, which the FDA recently approved

During the next 12 months, demand for early-stage contract projects could quickly exceed supply

PsiVac has generated compelling efficacy data in killing a broad range of tumour cells, including head and neck, bladder, liver, pancreatic and ovarian